Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Divalproex sodium + olanzapine is a combination of two psychiatric medications: divalproex sodium, a mood stabilizer primarily used as an anticonvulsant and for the treatment of bipolar disorder, and olanzapine, an atypical antipsychotic used for schizophrenia and bipolar disorder. The combination is used, particularly in adults, for the acute treatment of manic or mixed episodes in bipolar I disorder, especially when monotherapy is inadequate. Divalproex sodium increases brain concentrations of gamma-aminobutyric acid (GABA), inhibiting neuronal firing, while olanzapine antagonizes multiple neurotransmitter receptors, most notably dopamine D2 and serotonin 5-HT2A receptors, helping to stabilize mood and reduce psychotic symptoms. The combination aims to provide both mood stabilization and enhanced antipsychotic effects, with studies suggesting earlier and more robust symptom improvement compared to monotherapy, though benefits must be weighed against an increased risk of adverse effects such as weight gain or liver toxicity[1][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on divalproex sodium + olanzapine.